{"entity":{"id":"nct05496166","kind":"trial","name":"The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Canc","aka":[],"tldr":"A phase 3 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.","summary":"The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05496166 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 348 participants, started 2023-08-01 and due to reach its primary completion in 2027-08-01. Interventions recorded: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy. Conditions listed: Limited Stage Small Cell Lung Cancer. Primary outcome: progression-free survival. Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed SCLC, imaging examination and other confirmed limited-stage small cell lung cancer, and without previous treatment;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05496166","url":"https://clinicaltrials.gov/study/NCT05496166"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["limited-stage-sclc"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05496166","phase":"3","setting":"Comparing the Efficiency Between Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer: a Randomized, Controlled, Open-label, Single-center Phase III Clinical Trial","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","participation":[{"nct":"NCT05496166","source":"https://clinicaltrials.gov/study/NCT05496166","fetchedAt":"2026-10-07T16:53:43.406Z","studySha256":"70fe47819363793067e16eb2cc8396938132542de9bfe021eb2f10b5f23fe582","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2023-05-17","leadSponsor":"Shanghai Pulmonary Hospital, Shanghai, China","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":348,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2023-08-01","startedType":"estimated","enrolled":348,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05496166/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}